Delivery Order SPE2DB24D2010-SPE2DB25FAANU
- Not listed
- The Defense Logistics Agency awarded a $31,530.56 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Otezla 30 mg tablets (60-count packages). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 28, 2025. The delivery order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for supply of Otezla 30 mg tablets in quantities of 60 units. This firm fixed-price delivery order, valued at $48,488.62 with an ultimate completion date of July 30, 2025, represents a non-set-aside competitive award. The product will be delivered to AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $13,321.78 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Otezla 30 mg tablets (60-count packages) on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a non-set-aside competitive award issued as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.999 billion through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Otezla 30 mg tablets (60-count packaging) with a ceiling value of $27,320.78. This firm fixed-price delivery order, which is expected to be completed by July 24, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside designation, reflecting...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,785.70 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) under a firm fixed price contract. The award was issued on July 28, 2025, with an ultimate completion date of July 29, 2025. This delivery order represents a non-competitive purchase executed under an existing contract vehicle and will be performed at the vendor's location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a delivery order valued at $17,620.78 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and represents a continuation of pharmaceutical supply services under AmerisourceBergen's broader federal contract portfolio. The product will be delivered to the company's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) under a firm fixed-price contract valued at $43,076.07. This non-set-aside competitive award was issued on July 31, 2025, with an ultimate completion date of August 1, 2025. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Otezla 30 mg tablets (60-count) with a ceiling value of $10,754.26. This is a firm fixed-price delivery order with an ultimate completion date of July 31, 2025, and carries no set-aside designation, indicating it was competitively awarded. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 29, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a ceiling value of $10,324.90. This firm fixed-price delivery order, with an ultimate completion date of July 30, 2025, represents a single transaction under the company's broader pharmaceutical supply relationship with DLA. The award was not designated as a set-aside contract and was competitively awarded. Performance of...
- The Defense Logistics Agency awarded a $7,869.72 delivery order to AmerisourceBergen Drug Corp for 60-count tablets of Otezla 30 mg, a pharmaceutical product for treating autoimmune conditions. This competitive award, issued on July 22, 2025, represents a firm fixed-price contract with a completion date of July 23, 2025, and carries no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FAANUDelivery Order
The Defense Logistics Agency awarded a $36,477.84 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Otezla 30 mg tablets (60-count units). The contract is a firm fixed price delivery order with an ultimate completion date of July 30, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.999 billion global pharmaceutical support vehicle running through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen maintains an extensive portfolio of pharmaceutical products and medical supplies supporting military and veteran healthcare systems. The company's DLA contract encompasses brand-name and generic medications, vaccines, and specialized medical commodities across multiple therapeutic domains, enabling the delivery of essential pharmaceutical support to Defense Health Agency customers and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $36.5k | 7/29/25 |